img

Global Anti-VEGF Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anti-VEGF Market Insights, Forecast to 2034

Global Anti-VEGF market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Anti-VEGF industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2024, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Covers
This report presents an overview of global Anti-VEGF market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Anti-VEGF market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Amgen Inc.
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Xbrane Biopharma AB
Allergan, Bayer AG
Regeneron Pharmaceuticals Inc.
Viatris Inc. (Mylan)
Segment by Type
Avastin
Lucentis
Eylea

Segment by Application


Macular Edema
Diabetic Retinopathy
Retinal Vein Occlusion
Age-Related Macular Degeneration

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Anti-VEGF plant distribution, commercial date of Anti-VEGF, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Anti-VEGF introduction, etc. Anti-VEGF Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Anti-VEGF
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Anti-VEGF Product Introduction
1.2 Market by Type
1.2.1 Global Anti-VEGF Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Avastin
1.2.3 Lucentis
1.2.4 Eylea
1.3 Market by Application
1.3.1 Global Anti-VEGF Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Macular Edema
1.3.3 Diabetic Retinopathy
1.3.4 Retinal Vein Occlusion
1.3.5 Age-Related Macular Degeneration
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-VEGF Sales Estimates and Forecasts 2018-2029
2.2 Global Anti-VEGF Revenue by Region
2.2.1 Global Anti-VEGF Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Anti-VEGF Revenue by Region (2018-2024)
2.2.3 Global Anti-VEGF Revenue by Region (2024-2029)
2.2.4 Global Anti-VEGF Revenue Market Share by Region (2018-2029)
2.3 Global Anti-VEGF Sales Estimates and Forecasts 2018-2029
2.4 Global Anti-VEGF Sales by Region
2.4.1 Global Anti-VEGF Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Anti-VEGF Sales by Region (2018-2024)
2.4.3 Global Anti-VEGF Sales by Region (2024-2029)
2.4.4 Global Anti-VEGF Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Anti-VEGF Sales by Manufacturers
3.1.1 Global Anti-VEGF Sales by Manufacturers (2018-2024)
3.1.2 Global Anti-VEGF Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-VEGF in 2022
3.2 Global Anti-VEGF Revenue by Manufacturers
3.2.1 Global Anti-VEGF Revenue by Manufacturers (2018-2024)
3.2.2 Global Anti-VEGF Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-VEGF Revenue in 2022
3.3 Global Key Players of Anti-VEGF, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Anti-VEGF Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-VEGF Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-VEGF, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-VEGF, Product Offered and Application
3.8 Global Key Manufacturers of Anti-VEGF, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Anti-VEGF Sales by Type
4.1.1 Global Anti-VEGF Historical Sales by Type (2018-2024)
4.1.2 Global Anti-VEGF Forecasted Sales by Type (2024-2029)
4.1.3 Global Anti-VEGF Sales Market Share by Type (2018-2029)
4.2 Global Anti-VEGF Revenue by Type
4.2.1 Global Anti-VEGF Historical Revenue by Type (2018-2024)
4.2.2 Global Anti-VEGF Forecasted Revenue by Type (2024-2029)
4.2.3 Global Anti-VEGF Revenue Market Share by Type (2018-2029)
4.3 Global Anti-VEGF Price by Type
4.3.1 Global Anti-VEGF Price by Type (2018-2024)
4.3.2 Global Anti-VEGF Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Anti-VEGF Sales by Application
5.1.1 Global Anti-VEGF Historical Sales by Application (2018-2024)
5.1.2 Global Anti-VEGF Forecasted Sales by Application (2024-2029)
5.1.3 Global Anti-VEGF Sales Market Share by Application (2018-2029)
5.2 Global Anti-VEGF Revenue by Application
5.2.1 Global Anti-VEGF Historical Revenue by Application (2018-2024)
5.2.2 Global Anti-VEGF Forecasted Revenue by Application (2024-2029)
5.2.3 Global Anti-VEGF Revenue Market Share by Application (2018-2029)
5.3 Global Anti-VEGF Price by Application
5.3.1 Global Anti-VEGF Price by Application (2018-2024)
5.3.2 Global Anti-VEGF Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Anti-VEGF Market Size by Type
6.1.1 US & Canada Anti-VEGF Sales by Type (2018-2029)
6.1.2 US & Canada Anti-VEGF Revenue by Type (2018-2029)
6.2 US & Canada Anti-VEGF Market Size by Application
6.2.1 US & Canada Anti-VEGF Sales by Application (2018-2029)
6.2.2 US & Canada Anti-VEGF Revenue by Application (2018-2029)
6.3 US & Canada Anti-VEGF Market Size by Country
6.3.1 US & Canada Anti-VEGF Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Anti-VEGF Sales by Country (2018-2029)
6.3.3 US & Canada Anti-VEGF Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Anti-VEGF Market Size by Type
7.1.1 Europe Anti-VEGF Sales by Type (2018-2029)
7.1.2 Europe Anti-VEGF Revenue by Type (2018-2029)
7.2 Europe Anti-VEGF Market Size by Application
7.2.1 Europe Anti-VEGF Sales by Application (2018-2029)
7.2.2 Europe Anti-VEGF Revenue by Application (2018-2029)
7.3 Europe Anti-VEGF Market Size by Country
7.3.1 Europe Anti-VEGF Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Anti-VEGF Sales by Country (2018-2029)
7.3.3 Europe Anti-VEGF Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Anti-VEGF Market Size
8.1.1 China Anti-VEGF Sales (2018-2029)
8.1.2 China Anti-VEGF Revenue (2018-2029)
8.2 China Anti-VEGF Market Size by Application
8.2.1 China Anti-VEGF Sales by Application (2018-2029)
8.2.2 China Anti-VEGF Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Anti-VEGF Market Size by Type
9.1.1 Asia Anti-VEGF Sales by Type (2018-2029)
9.1.2 Asia Anti-VEGF Revenue by Type (2018-2029)
9.2 Asia Anti-VEGF Market Size by Application
9.2.1 Asia Anti-VEGF Sales by Application (2018-2029)
9.2.2 Asia Anti-VEGF Revenue by Application (2018-2029)
9.3 Asia Anti-VEGF Sales by Region
9.3.1 Asia Anti-VEGF Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Anti-VEGF Revenue by Region (2018-2029)
9.3.3 Asia Anti-VEGF Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-VEGF Market Size by Type
10.1.1 Middle East, Africa and Latin America Anti-VEGF Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Anti-VEGF Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Anti-VEGF Market Size by Application
10.2.1 Middle East, Africa and Latin America Anti-VEGF Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Anti-VEGF Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Anti-VEGF Sales by Country
10.3.1 Middle East, Africa and Latin America Anti-VEGF Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Anti-VEGF Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Anti-VEGF Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Information
11.1.2 Amgen Inc. Overview
11.1.3 Amgen Inc. Anti-VEGF Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Amgen Inc. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Amgen Inc. Recent Developments
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 F. Hoffmann-La Roche Ltd. Company Information
11.2.2 F. Hoffmann-La Roche Ltd. Overview
11.2.3 F. Hoffmann-La Roche Ltd. Anti-VEGF Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 F. Hoffmann-La Roche Ltd. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 F. Hoffmann-La Roche Ltd. Recent Developments
11.3 Pfizer, Inc.
11.3.1 Pfizer, Inc. Company Information
11.3.2 Pfizer, Inc. Overview
11.3.3 Pfizer, Inc. Anti-VEGF Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Pfizer, Inc. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer, Inc. Recent Developments
11.4 Xbrane Biopharma AB
11.4.1 Xbrane Biopharma AB Company Information
11.4.2 Xbrane Biopharma AB Overview
11.4.3 Xbrane Biopharma AB Anti-VEGF Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Xbrane Biopharma AB Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Xbrane Biopharma AB Recent Developments
11.5 Allergan, Bayer AG
11.5.1 Allergan, Bayer AG Company Information
11.5.2 Allergan, Bayer AG Overview
11.5.3 Allergan, Bayer AG Anti-VEGF Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Allergan, Bayer AG Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Allergan, Bayer AG Recent Developments
11.6 Regeneron Pharmaceuticals Inc.
11.6.1 Regeneron Pharmaceuticals Inc. Company Information
11.6.2 Regeneron Pharmaceuticals Inc. Overview
11.6.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Regeneron Pharmaceuticals Inc. Recent Developments
11.7 Viatris Inc. (Mylan)
11.7.1 Viatris Inc. (Mylan) Company Information
11.7.2 Viatris Inc. (Mylan) Overview
11.7.3 Viatris Inc. (Mylan) Anti-VEGF Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Viatris Inc. (Mylan) Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Viatris Inc. (Mylan) Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-VEGF Industry Chain Analysis
12.2 Anti-VEGF Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-VEGF Production Mode & Process
12.4 Anti-VEGF Sales and Marketing
12.4.1 Anti-VEGF Sales Channels
12.4.2 Anti-VEGF Distributors
12.5 Anti-VEGF Customers
13 Market Dynamics
13.1 Anti-VEGF Industry Trends
13.2 Anti-VEGF Market Drivers
13.3 Anti-VEGF Market Challenges
13.4 Anti-VEGF Market Restraints
14 Key Findings in The Global Anti-VEGF Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-VEGF Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Avastin
Table 3. Major Manufacturers of Lucentis
Table 4. Major Manufacturers of Eylea
Table 5. Global Anti-VEGF Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Anti-VEGF Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Anti-VEGF Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Anti-VEGF Revenue by Region (2024-2029) & (US$ Million)
Table 9. Global Anti-VEGF Revenue Market Share by Region (2018-2024)
Table 10. Global Anti-VEGF Revenue Market Share by Region (2024-2029)
Table 11. Global Anti-VEGF Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Anti-VEGF Sales by Region (2018-2024) & (K Units)
Table 13. Global Anti-VEGF Sales by Region (2024-2029) & (K Units)
Table 14. Global Anti-VEGF Sales Market Share by Region (2018-2024)
Table 15. Global Anti-VEGF Sales Market Share by Region (2024-2029)
Table 16. Global Anti-VEGF Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Anti-VEGF Sales Share by Manufacturers (2018-2024)
Table 18. Global Anti-VEGF Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Anti-VEGF Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Anti-VEGF, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Anti-VEGF Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Anti-VEGF Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Anti-VEGF by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF as of 2022)
Table 24. Global Key Manufacturers of Anti-VEGF, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Anti-VEGF, Product Offered and Application
Table 26. Global Key Manufacturers of Anti-VEGF, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Anti-VEGF Sales by Type (2018-2024) & (K Units)
Table 29. Global Anti-VEGF Sales by Type (2024-2029) & (K Units)
Table 30. Global Anti-VEGF Sales Share by Type (2018-2024)
Table 31. Global Anti-VEGF Sales Share by Type (2024-2029)
Table 32. Global Anti-VEGF Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Anti-VEGF Revenue by Type (2024-2029) & (US$ Million)
Table 34. Global Anti-VEGF Revenue Share by Type (2018-2024)
Table 35. Global Anti-VEGF Revenue Share by Type (2024-2029)
Table 36. Anti-VEGF Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Anti-VEGF Price Forecast by Type (2024-2029) & (US$/Unit)
Table 38. Global Anti-VEGF Sales by Application (2018-2024) & (K Units)
Table 39. Global Anti-VEGF Sales by Application (2024-2029) & (K Units)
Table 40. Global Anti-VEGF Sales Share by Application (2018-2024)
Table 41. Global Anti-VEGF Sales Share by Application (2024-2029)
Table 42. Global Anti-VEGF Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Anti-VEGF Revenue by Application (2024-2029) & (US$ Million)
Table 44. Global Anti-VEGF Revenue Share by Application (2018-2024)
Table 45. Global Anti-VEGF Revenue Share by Application (2024-2029)
Table 46. Anti-VEGF Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Anti-VEGF Price Forecast by Application (2024-2029) & (US$/Unit)
Table 48. US & Canada Anti-VEGF Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Anti-VEGF Sales by Type (2024-2029) & (K Units)
Table 50. US & Canada Anti-VEGF Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Anti-VEGF Revenue by Type (2024-2029) & (US$ Million)
Table 52. US & Canada Anti-VEGF Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Anti-VEGF Sales by Application (2024-2029) & (K Units)
Table 54. US & Canada Anti-VEGF Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Anti-VEGF Revenue by Application (2024-2029) & (US$ Million)
Table 56. US & Canada Anti-VEGF Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 57. US & Canada Anti-VEGF Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Anti-VEGF Revenue by Country (2024-2029) & (US$ Million)
Table 59. US & Canada Anti-VEGF Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Anti-VEGF Sales by Country (2024-2029) & (K Units)
Table 61. Europe Anti-VEGF Sales by Type (2018-2024) & (K Units)
Table 62. Europe Anti-VEGF Sales by Type (2024-2029) & (K Units)
Table 63. Europe Anti-VEGF Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Anti-VEGF Revenue by Type (2024-2029) & (US$ Million)
Table 65. Europe Anti-VEGF Sales by Application (2018-2024) & (K Units)
Table 66. Europe Anti-VEGF Sales by Application (2024-2029) & (K Units)
Table 67. Europe Anti-VEGF Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Anti-VEGF Revenue by Application (2024-2029) & (US$ Million)
Table 69. Europe Anti-VEGF Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 70. Europe Anti-VEGF Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Anti-VEGF Revenue by Country (2024-2029) & (US$ Million)
Table 72. Europe Anti-VEGF Sales by Country (2018-2024) & (K Units)
Table 73. Europe Anti-VEGF Sales by Country (2024-2029) & (K Units)
Table 74. China Anti-VEGF Sales by Type (2018-2024) & (K Units)
Table 75. China Anti-VEGF Sales by Type (2024-2029) & (K Units)
Table 76. China Anti-VEGF Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Anti-VEGF Revenue by Type (2024-2029) & (US$ Million)
Table 78. China Anti-VEGF Sales by Application (2018-2024) & (K Units)
Table 79. China Anti-VEGF Sales by Application (2024-2029) & (K Units)
Table 80. China Anti-VEGF Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Anti-VEGF Revenue by Application (2024-2029) & (US$ Million)
Table 82. Asia Anti-VEGF Sales by Type (2018-2024) & (K Units)
Table 83. Asia Anti-VEGF Sales by Type (2024-2029) & (K Units)
Table 84. Asia Anti-VEGF Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Anti-VEGF Revenue by Type (2024-2029) & (US$ Million)
Table 86. Asia Anti-VEGF Sales by Application (2018-2024) & (K Units)
Table 87. Asia Anti-VEGF Sales by Application (2024-2029) & (K Units)
Table 88. Asia Anti-VEGF Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Anti-VEGF Revenue by Application (2024-2029) & (US$ Million)
Table 90. Asia Anti-VEGF Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 91. Asia Anti-VEGF Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Anti-VEGF Revenue by Region (2024-2029) & (US$ Million)
Table 93. Asia Anti-VEGF Sales by Region (2018-2024) & (K Units)
Table 94. Asia Anti-VEGF Sales by Region (2024-2029) & (K Units)
Table 95. Middle East, Africa and Latin America Anti-VEGF Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Anti-VEGF Sales by Type (2024-2029) & (K Units)
Table 97. Middle East, Africa and Latin America Anti-VEGF Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Anti-VEGF Revenue by Type (2024-2029) & (US$ Million)
Table 99. Middle East, Africa and Latin America Anti-VEGF Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Anti-VEGF Sales by Application (2024-2029) & (K Units)
Table 101. Middle East, Africa and Latin America Anti-VEGF Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Anti-VEGF Revenue by Application (2024-2029) & (US$ Million)
Table 103. Middle East, Africa and Latin America Anti-VEGF Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 104. Middle East, Africa and Latin America Anti-VEGF Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Anti-VEGF Revenue by Country (2024-2029) & (US$ Million)
Table 106. Middle East, Africa and Latin America Anti-VEGF Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Anti-VEGF Sales by Country (2024-2029) & (K Units)
Table 108. Amgen Inc. Company Information
Table 109. Amgen Inc. Description and Major Businesses
Table 110. Amgen Inc. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Amgen Inc. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Amgen Inc. Recent Developments
Table 113. F. Hoffmann-La Roche Ltd. Company Information
Table 114. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 115. F. Hoffmann-La Roche Ltd. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. F. Hoffmann-La Roche Ltd. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. F. Hoffmann-La Roche Ltd. Recent Developments
Table 118. Pfizer, Inc. Company Information
Table 119. Pfizer, Inc. Description and Major Businesses
Table 120. Pfizer, Inc. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Pfizer, Inc. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Pfizer, Inc. Recent Developments
Table 123. Xbrane Biopharma AB Company Information
Table 124. Xbrane Biopharma AB Description and Major Businesses
Table 125. Xbrane Biopharma AB Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Xbrane Biopharma AB Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Xbrane Biopharma AB Recent Developments
Table 128. Allergan, Bayer AG Company Information
Table 129. Allergan, Bayer AG Description and Major Businesses
Table 130. Allergan, Bayer AG Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Allergan, Bayer AG Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Allergan, Bayer AG Recent Developments
Table 133. Regeneron Pharmaceuticals Inc. Company Information
Table 134. Regeneron Pharmaceuticals Inc. Description and Major Businesses
Table 135. Regeneron Pharmaceuticals Inc. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Regeneron Pharmaceuticals Inc. Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Regeneron Pharmaceuticals Inc. Recent Developments
Table 138. Viatris Inc. (Mylan) Company Information
Table 139. Viatris Inc. (Mylan) Description and Major Businesses
Table 140. Viatris Inc. (Mylan) Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Viatris Inc. (Mylan) Anti-VEGF Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Viatris Inc. (Mylan) Recent Developments
Table 143. Key Raw Materials Lists
Table 144. Raw Materials Key Suppliers Lists
Table 145. Anti-VEGF Distributors List
Table 146. Anti-VEGF Customers List
Table 147. Anti-VEGF Market Trends
Table 148. Anti-VEGF Market Drivers
Table 149. Anti-VEGF Market Challenges
Table 150. Anti-VEGF Market Restraints
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-VEGF Product Picture
Figure 2. Global Anti-VEGF Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Anti-VEGF Market Share by Type in 2022 & 2029
Figure 4. Avastin Product Picture
Figure 5. Lucentis Product Picture
Figure 6. Eylea Product Picture
Figure 7. Global Anti-VEGF Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 8. Global Anti-VEGF Market Share by Application in 2022 & 2029
Figure 9. Macular Edema
Figure 10. Diabetic Retinopathy
Figure 11. Retinal Vein Occlusion
Figure 12. Age-Related Macular Degeneration
Figure 13. Anti-VEGF Report Years Considered
Figure 14. Global Anti-VEGF Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Anti-VEGF Revenue 2018-2029 (US$ Million)
Figure 16. Global Anti-VEGF Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 17. Global Anti-VEGF Revenue Market Share by Region (2018-2029)
Figure 18. Global Anti-VEGF Sales 2018-2029 ((K Units)
Figure 19. Global Anti-VEGF Sales Market Share by Region (2018-2029)
Figure 20. US & Canada Anti-VEGF Sales YoY (2018-2029) & (K Units)
Figure 21. US & Canada Anti-VEGF Revenue YoY (2018-2029) & (US$ Million)
Figure 22. Europe Anti-VEGF Sales YoY (2018-2029) & (K Units)
Figure 23. Europe Anti-VEGF Revenue YoY (2018-2029) & (US$ Million)
Figure 24. China Anti-VEGF Sales YoY (2018-2029) & (K Units)
Figure 25. China Anti-VEGF Revenue YoY (2018-2029) & (US$ Million)
Figure 26. Asia (excluding China) Anti-VEGF Sales YoY (2018-2029) & (K Units)
Figure 27. Asia (excluding China) Anti-VEGF Revenue YoY (2018-2029) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Anti-VEGF Sales YoY (2018-2029) & (K Units)
Figure 29. Middle East, Africa and Latin America Anti-VEGF Revenue YoY (2018-2029) & (US$ Million)
Figure 30. The Anti-VEGF Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Anti-VEGF in the World: Market Share by Anti-VEGF Revenue in 2022
Figure 32. Global Anti-VEGF Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Anti-VEGF Sales Market Share by Type (2018-2029)
Figure 34. Global Anti-VEGF Revenue Market Share by Type (2018-2029)
Figure 35. Global Anti-VEGF Sales Market Share by Application (2018-2029)
Figure 36. Global Anti-VEGF Revenue Market Share by Application (2018-2029)
Figure 37. US & Canada Anti-VEGF Sales Market Share by Type (2018-2029)
Figure 38. US & Canada Anti-VEGF Revenue Market Share by Type (2018-2029)
Figure 39. US & Canada Anti-VEGF Sales Market Share by Application (2018-2029)
Figure 40. US & Canada Anti-VEGF Revenue Market Share by Application (2018-2029)
Figure 41. US & Canada Anti-VEGF Revenue Share by Country (2018-2029)
Figure 42. US & Canada Anti-VEGF Sales Share by Country (2018-2029)
Figure 43. U.S. Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 44. Canada Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 45. Europe Anti-VEGF Sales Market Share by Type (2018-2029)
Figure 46. Europe Anti-VEGF Revenue Market Share by Type (2018-2029)
Figure 47. Europe Anti-VEGF Sales Market Share by Application (2018-2029)
Figure 48. Europe Anti-VEGF Revenue Market Share by Application (2018-2029)
Figure 49. Europe Anti-VEGF Revenue Share by Country (2018-2029)
Figure 50. Europe Anti-VEGF Sales Share by Country (2018-2029)
Figure 51. Germany Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 52. France Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 53. U.K. Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 54. Italy Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 55. Russia Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 56. China Anti-VEGF Sales Market Share by Type (2018-2029)
Figure 57. China Anti-VEGF Revenue Market Share by Type (2018-2029)
Figure 58. China Anti-VEGF Sales Market Share by Application (2018-2029)
Figure 59. China Anti-VEGF Revenue Market Share by Application (2018-2029)
Figure 60. Asia Anti-VEGF Sales Market Share by Type (2018-2029)
Figure 61. Asia Anti-VEGF Revenue Market Share by Type (2018-2029)
Figure 62. Asia Anti-VEGF Sales Market Share by Application (2018-2029)
Figure 63. Asia Anti-VEGF Revenue Market Share by Application (2018-2029)
Figure 64. Asia Anti-VEGF Revenue Share by Region (2018-2029)
Figure 65. Asia Anti-VEGF Sales Share by Region (2018-2029)
Figure 66. Japan Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 67. South Korea Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 68. China Taiwan Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 69. Southeast Asia Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 70. India Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Anti-VEGF Sales Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Anti-VEGF Revenue Market Share by Type (2018-2029)
Figure 73. Middle East, Africa and Latin America Anti-VEGF Sales Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Anti-VEGF Revenue Market Share by Application (2018-2029)
Figure 75. Middle East, Africa and Latin America Anti-VEGF Revenue Share by Country (2018-2029)
Figure 76. Middle East, Africa and Latin America Anti-VEGF Sales Share by Country (2018-2029)
Figure 77. Brazil Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 78. Mexico Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 79. Turkey Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 80. Israel Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 81. GCC Countries Anti-VEGF Revenue (2018-2029) & (US$ Million)
Figure 82. Anti-VEGF Value Chain
Figure 83. Anti-VEGF Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries